Excellent results.
The way that the announcement is written, I'm unsure whether the SD and PR are independent of each other. If they are, then this appears to be a little sleeper - 85% DCR.
From what I can tell, they've simply run a P1b/2a that mimicks the below P3 trial and just added Narmafotinib. Unsure of other clinical competitors used in combination with paclitaxel/gemcitabine in advanced pancreatic cancer, but the results are compelling so far.
The next key measures are obviously OS & PFS, but that will come with time.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1304369
(20min delay)